Live Price Coverage: Sarepta Therapeutics Inc Has Another Very Strong Trading Session

Live Price Coverage: Sarepta Therapeutics Inc Has Another Very Strong Trading Session

The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! About 489,422 shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 231.40% since April 21, 2016 and is uptrending. It has outperformed by 226.07% the S&P500.
The move comes after 7 months positive chart setup for the $1.97B company. It was reported on Nov, 23 by Barchart.com. We have $40.61 PT which if reached, will make NASDAQ:SRPT worth $177.30 million more.

Analysts await Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings on February, 23. They expect $-1.24 earnings per share, up 13.89% or $0.20 from last year’s $-1.44 per share. After $-1.10 actual earnings per share reported by Sarepta Therapeutics Inc for the previous quarter, Wall Street now forecasts 12.73% negative EPS growth.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Friday, April 29 the stock rating was downgraded by Jefferies to “Underperform”. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Neutral” rating by Wedbush on Thursday, April 21. As per Friday, October 23, the company rating was initiated by Jefferies. The stock has “Buy” rating given by Vetr on Tuesday, August 25. Oppenheimer maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Wednesday, April 6. Oppenheimer has “Outperform” rating and $60 price target. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned “Buy” rating by Janney Capital on Monday, September 19. Wedbush maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) on Wednesday, July 20 with “Outperform” rating. Jefferies upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) on Monday, September 19 to “Hold” rating. As per Friday, July 22, the company rating was maintained by Needham. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Friday, October 28 by RBC Capital Markets.

According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.52 in Q2 2016. Its up 0.36, from 1.16 in 2016Q1. The ratio is positive, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Moreover, Oppenheimer & Company has 0.01% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 20,213 shares. The New Jersey-based Sabby Management Limited Liability Company has invested 0.78% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Ladenburg Thalmann Finance Ser Inc has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Bank & Trust Of New York Mellon Corp accumulated 221,818 shares or 0% of the stock. Jane Street Gru Limited Liability Corp accumulated 38,547 shares or 0% of the stock. Barclays Public Ltd Company has 0.01% invested in the company for 207,310 shares. Moreover, State Board Of Administration Of Florida Retirement Sys has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 33,135 shares. Manufacturers Life Ins The holds 0% or 29,280 shares in its portfolio. Mangrove Ptnrs holds 2.34% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 492,500 shares. Commonwealth Equity Serv Inc accumulated 0% or 15,828 shares. Teacher Retirement System Of Texas has 0% invested in the company for 6,034 shares. The New York-based Millennium Mgmt Lc has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). California State Teachers Retirement Systems accumulated 0% or 89,609 shares. Amici Limited Liability Corp accumulated 0.09% or 25,000 shares. Moreover, Grp has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 24,601 shares.

Insider Transactions: Since September 14, 2016, the stock had 0 insider buys, and 8 insider sales for $8.94 million net activity. Howton David T also sold $420,000 worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) shares. Ruff Shamim sold $438,660 worth of stock. 35,000 shares were sold by Aphale Jayant, worth $1.75 million on Monday, September 19. $736,710 worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) was sold by Kaye Edward M. MD. $1.50M worth of Sarepta Therapeutics Inc (NASDAQ:SRPT) shares were sold by Mahatme Sandesh.

SRPT Company Profile

Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment